Pfizer, Novartis lead $2 billion spending spree on gene therapy production

Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world's priciest medicines.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Philadelphia gene therapy startup Limelight Bio, whose founders include researchers from the University of Pennsylvania Perelman School of Medicine and Children's Hospital of Philadelphia, has raised $75 million in venture capital financing. The investment in Limelight was made by Apple Tree Partners, a life sciences innovation fund based in New York City that also provided seed funding to launch Limelight in late 2016. Limelight is developing proprietary technologies designed to overcome limitations…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
In this study, the DNA translocation process through POPC (1-palmitoyl-2-oleoylphosphatidylcholine) membrane with the assistance of CNTs was explored by molecular dynamics (MD) simulation. Our simulation results demonstrated that the CNTs could insert steadily into the POPC membrane, and DNA molecules tends to insert into the inner space of CNTs. With the assistance of CNTs, the free energy of nucleotides passing through the POPC membrane decreases. Moreover, the free energy of nucleotides (DA (deoxyadenosine), DT (deoxythymidine), DC (deoxycytidine), and DG (deoxyguanosine)) passing through POPC membrane follows the order...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Human Gene Therapy, Ahead of Print.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
Condition:   Epidermolysis Bullosa Dystrophica, Recessive Intervention:   Biological: COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin Sponsor:   Institut National de la Santé Et de la Recherche Médicale, France Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study mainly explored the mechanism of TRPC5 gene in the treatment of spinal cord ischemia reperfusion injury from the perspective of angiogenesis. Western blot, immunohistochemistry, hematoxylin and eosin, ELISA, and reverse transcription-PCR (RT-PCR) were used to detect the expression levels of related angiogenic proteins such as von Willebrend factor (vWF), vascular endothelial growth factor (VEGF), CD31, and HIF-1α. The results showed that compared with the IR group, the Basso, Beattie, and Bresnahan scores of IR + adeno-associated virus (AAV) + TRPC5 group were higher with significant difference. And compar...
Source: NeuroReport - Category: Neurology Tags: Cellular, Molecular and Developmental Neuroscience Source Type: research
Novartis research head Jay Bradner said on Thursday the Swiss drugmaker is focusing drug development efforts against spinal muscular atrophy on gene therapy Zolgensma and retreating from oral therapy like its molecule LMI070, also called branaplam.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Philadelphia gene therapy startup Limelight Bio, whose founders include researchers from the University of Pennsylvania Perelman School of Medicine and Children's Hospital of Philadelphia, has raised $75 million in venture capital financing. The investment in Limelight was made by Apple Tree Partners, a life sciences innovation fund based in New York City that also provided seed funding to launch Limelight in late 2016. Limelight is developing proprietary technologies designed to overcome limitations…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
No abstract available
Source: Neurology Today - Category: Neurology Tags: At the Bench Source Type: research
Publication date: Available online 28 November 2019Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Jiamin Rong, Pengcheng Li, Yakun Ge, Hongling Chen, Jie Wu, Renwen Zhang, Jun Lao, Dawei Lou, Yuanxin ZhangAbstractThe design and development of advanced gene/drug codelivery nanocarrier with good biocompatibility for cancer gene therapy is desirable. Herein, we reported a gene delivery nanoplatform to synergized bortezomib (BTZ) for cancer treatment with histone H2A-hybrided, upconversion luminescence (UCL)-guided mesoporous silica nanoparticles [UCNPs(BTZ)@mSiO2-H2A]. The functionalization of H2A on the surface of ...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
Japan's Astellas Pharma Inc is buying U.S. drugmaker Audentes Therapeutics Inc for about $3 billion in cash, in a high-priced push to make genetic medicines a key area of growth.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Family Medicine/Primary Care News Source Type: news
More News: Gene Therapy | Genetics | Health | Pfizer